BridgeBio Oncology Therapeutics (BBOT) has unveiled promising preclinical data for BBO-11818, a selective, orally bioavailable non-covalent inhibitor targeting both active (GTP-bound) and inactive (GDP-bound) states of KRAS. This dual-state targeting effectively suppresses MAPK signaling and inhibits cell proliferation in KRAS-mutant cell lines, showcasing robust anti-tumor activity across various KRAS-mutant cancer models. The findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting BBO-11818’s potential as a novel therapeutic option for cancers driven by KRAS mutations, particularly KRASG12D and KRASG12V variants.

The significance of BBO-11818 lies in its ability to address a critical unmet need in oncology, as current treatment options for KRAS-mutant cancers are limited. The data indicates that BBO-11818 not only inhibits ERK phosphorylation and proliferation in KRAS-dependent cell lines but also demonstrates enhanced efficacy when combined with other agents such as BBO-10203, cetuximab, and anti-PD-1 therapies. This combination approach has shown to induce complete tumor regressions and stimulate an adaptive immune response in preclinical models, suggesting a synergistic effect that could improve patient outcomes in KRAS-driven malignancies.

The implications for future research and drug development are significant. BBO-11818’s unique mechanism of action may shift the current paradigms in targeting KRAS mutations, potentially accelerating the timeline for clinical applications in treating KRAS-mutant cancers. As BBOT progresses into Phase 1 clinical trials with BBO-11818, the oncology community will be closely monitoring its performance and the potential for establishing a new standard of care for patients with these challenging tumors.

Source: globenewswire.com